Khalid Sidra, Daw Hamed
Internal Medicine, Fairview Hospital, Cleveland Clinic, USA.
Department of Hematology and Oncology, Fairview Hospital, Cleveland Clinic, USA.
Cureus. 2017 Jul 5;9(7):e1428. doi: 10.7759/cureus.1428.
Heparin-induced thrombocytopenia (HIT) can present as arterial and venous thrombosis in adults who are treated with heparin. We present a case of a patient who developed HIT when she was treated for deep venous thrombosis (DVT) and pulmonary embolism with heparin. During the treatment with heparin and while being transitioned to warfarin, she developed arterial thrombosis. A work-up for HIT was sent, and it was positive. She was started on the argatroban drip and her platelet counts stabilized. Since her platelet counts remained stable and were not increasing for three weeks, we decided to transition the patient to an oral anticoagulant. She was started on apixaban, a novel oral anticoagulant (NOAC), and her platelet counts remained stable. Therefore, through this case, we highlight the importance of platelet counts remaining stable when a patient with HIT is treated with apixaban.
肝素诱导的血小板减少症(HIT)可表现为接受肝素治疗的成人出现动脉和静脉血栓形成。我们报告一例患者,她在接受肝素治疗深静脉血栓形成(DVT)和肺栓塞时发生了HIT。在肝素治疗期间以及过渡到华法林的过程中,她发生了动脉血栓形成。针对HIT进行了检查,结果呈阳性。她开始接受阿加曲班静脉滴注,血小板计数稳定下来。由于她的血小板计数在三周内保持稳定且未上升,我们决定将患者过渡到口服抗凝剂。她开始服用新型口服抗凝剂(NOAC)阿哌沙班,血小板计数保持稳定。因此,通过这个病例,我们强调了HIT患者接受阿哌沙班治疗时血小板计数保持稳定的重要性。